Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is listed today as Allogene Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2018 | $412 M | No. 1 | $250 million to $1 billion | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Allogene Therapeutics, Inc., its revenue in fiscal 2024 came from these business segments: Reportable $20,000 (100%).
Annual report (SEC XBRL) · Dec 2024
Allogene Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2018).
SEC Form D · Apr 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2018
Products and services#
No products or services of Allogene Therapeutics, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Franz B. Humer | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Joshua A. Kazam | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Owen N. Witte | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Pfizer Inc | Fund or asset manager | not stated | not stated | Held Series A-1 preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 23 investors.
Largest shareholders today
Institutions holding Allogene Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$49 M8.93%
- Citadel Advisors LLC$39 M7.09%
- Frazier Life Sciences Management, L.P.$36 M6.48%
- Pfizer Inc$35 M6.36%
- State Street Corp$26 M4.71%
- Primecap Management Co/ca/$21 M3.79%
- Vanguard Capital Management LLC$19 M3.48%
- UBS Group AG$17 M3.09%
- FMR LLC$17 M3.06%
- Sio Capital Management, LLC$15 M2.63%
- Two Sigma Investments, LP$14 M2.60%
- Marshall Wace, LLP$13 M2.30%
- Geode Capital Management, LLC$10 M1.86%
- Candriam S.C.A.$9 M1.57%
- Goldman Sachs Group Inc$9 M1.54%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David M. Tanen | Executive officer | Apr 2018 |
| Joshua A. Kazam | Executive officer | Apr 2018 |
| Arie M. Belldegrun | Director | Apr 2018 |
| David M. Bonderman | Director | Apr 2018 |
| David M. Chang | Director | Apr 2018 |
| Franz M. Humer | Director | Apr 2018 |
| John M. Deyoung | Director | Apr 2018 |
| Joshua A. Kazam | Director | Apr 2018 |
| Owen M. Witte | Director | Apr 2018 |
| Robert M. Abraham | Director | Apr 2018 |
| Todd M. Sisitsky | Director | Apr 2018 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.